European Union · Question · QUESTION_WRITTEN
E-9-2024-000242
Evaluation of the administration of triptorelin in pediatrics for the treatment of gender dysphoria
Introduced
25 January 2024
Last action
—
Status
answered
Sponsors
—
Subjects
Discovery layer
Source updated
4 April 2024
Records
Official question E-9-2024-000242 from European Union at European Parliament. Dated 25 January 2024. Status: answered.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
5 official files
Evaluation of the administration of triptorelin in paediatrics for the treatment of gender dysphoria
Evaluation of the administration of triptorelin in paediatrics for the treatment of gender dysphoria
QUESTION_WRITTEN · EN · 6 February 2024
Evaluation of the administration of triptorelin in paediatrics for the treatment of gender dysphoria
QUESTION_WRITTEN · EN · 6 February 2024
Answer
QUESTION_WRITTEN_ANSWER · 4 April 2024
Valutazione della somministrazione della triptorelina in pediatria per il trattamento della disforia di genere
QUESTION_WRITTEN · IT · 6 February 2024
Valutazione della somministrazione della triptorelina in pediatria per il trattamento della disforia di genere
QUESTION_WRITTEN · IT · 6 February 2024
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.